MATINAS BIOPHARMA HOLDINGS, INC. (OTCMKTS:MTNB) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
On April 3, 2017, Matinas BioPharma Holdings, Inc. (the Company)
issued a press release announcing its financial results for the
year ended December 31, 2016. The full text of the press release
is furnished as Exhibit 99.1 hereto and is incorporated by
reference herein.
The information in this Item 2.02 of this Current Report on Form
8-K and Exhibit 99.1 attached hereto shall not be deemed filed
for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the Exchange Act), or otherwise subject to the
liabilities of that Section, nor shall such information be deemed
incorporated by reference in any filing under the Securities Act
of 1933, as amended (the Securities Act), or the Exchange Act,
except as shall be expressly set forth by specific reference in
such a filing.
Item 7.01. Regulation FD Disclosure.
The Company intends to use the presentation included as Exhibit
99.2 to this report in connection with a conference call on April
3, 2017 reporting financial results for 2016 and providing a
business outlook for 2017.
In accordance with General Instruction B.2 of Form 8-K, the
information in this Current Report on Form 8-K, including
Exhibits 99.2, shall not be deemed filed for the purposes of
Section 18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference in
any filing under the Exchange Act or the Securities Act of 1933,
as amended, except as shall be expressly set forth by specific
reference in such a filing.
Item 9.01.Financial Statements and Exhibits
| Exhibit | Description | |
| 99.1 | Press Release, dated April 3, 2017 | |
| 99.2 | Conference Call Presentation, dated April 3, 2017 |
About MATINAS BIOPHARMA HOLDINGS, INC. (OTCMKTS:MTNB)
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections. Its cochleate delivery technology platform is designed for the targeted delivery of pharmaceuticals directly to the site of infection or inflammation. Its MAT 2203 is an oral formulation of a spectrum anti-fungal drug called amphotericin B, which uses its cochleate delivery technology. Its MAT2501 is an orally administered, encochleated formulation of the spectrum aminoglycoside antibiotic amikacin, which may be used to treat different types of multidrug-resistant bacteria, including non-tubercular mycobacterial infections (NTM), as well as various multidrug-resistant gram negative and intracellular bacterial infections. MATINAS BIOPHARMA HOLDINGS, INC. (OTCMKTS:MTNB) Recent Trading Information
MATINAS BIOPHARMA HOLDINGS, INC. (OTCMKTS:MTNB) closed its last trading session up +0.02 at 2.77 with 326,344 shares trading hands.
